CD274 and head and neck squamous cell carcinoma: ICB with PD-1/PD-L1 inhibitors counteracts immunosuppression by restoring T-cell function, showing expanding clinical utility in HNSCC (19, 20), while dMMR/MSI-H tumors exhibit heightened sensitivity to ICIs due to their enhanced immunogenicity (21–23).